Dave Knapp

And so in establishing 503B pharmacies, they've established basically a pharmacy that's not like a traditional pharmacy. It's a factory. It is a plant that can mass produce medicines. And unlike 503As that have to hold an individual script for a patient, if a drug goes into an FDA shortage, they can mass produce it.

and sort of fill in the gaps for where the drug manufacturers can't meet the demand or import enough, et cetera, et cetera. Now, back these medications because of their efficacy, because they are leveling the metabolic playing field, and because the disease of obesity and diabetes are so prevalent in the United States, These went almost immediately into shortage.

and sort of fill in the gaps for where the drug manufacturers can't meet the demand or import enough, et cetera, et cetera. Now, back these medications because of their efficacy, because they are leveling the metabolic playing field, and because the disease of obesity and diabetes are so prevalent in the United States, These went almost immediately into shortage.

and sort of fill in the gaps for where the drug manufacturers can't meet the demand or import enough, et cetera, et cetera. Now, back these medications because of their efficacy, because they are leveling the metabolic playing field, and because the disease of obesity and diabetes are so prevalent in the United States, These went almost immediately into shortage.

People like me started making content about it. They haven't even really had to advertise these that much. Of course, everybody knows the Ozempic song, so they have been advertised to some extent. But once people really started to realize that these are absolute metabolic game changers, it's like everybody and their sisters on them.

People like me started making content about it. They haven't even really had to advertise these that much. Of course, everybody knows the Ozempic song, so they have been advertised to some extent. But once people really started to realize that these are absolute metabolic game changers, it's like everybody and their sisters on them.

People like me started making content about it. They haven't even really had to advertise these that much. Of course, everybody knows the Ozempic song, so they have been advertised to some extent. But once people really started to realize that these are absolute metabolic game changers, it's like everybody and their sisters on them.

There's just no way these two drug companies have been able to keep up. So they've been in shortage. The problem with that system is that these are... essentially a handshake agreement between big pharma and the fda that says yes our drug is in shortage or no it's not in shortage and so when october of 2024 hit eli lilly

There's just no way these two drug companies have been able to keep up. So they've been in shortage. The problem with that system is that these are... essentially a handshake agreement between big pharma and the fda that says yes our drug is in shortage or no it's not in shortage and so when october of 2024 hit eli lilly

There's just no way these two drug companies have been able to keep up. So they've been in shortage. The problem with that system is that these are... essentially a handshake agreement between big pharma and the fda that says yes our drug is in shortage or no it's not in shortage and so when october of 2024 hit eli lilly

reported to the FDA that Manjaro and Zepbound, which Terzepatide, it's probably the, not probably, it is probably the most powerful anti-obesity medication and type 2 diabetes medication on the market. It's like the next generation of Ozempic. They said... our stuff is commercially available, which set off a chain reaction of stopping the 503 manufacturing.

reported to the FDA that Manjaro and Zepbound, which Terzepatide, it's probably the, not probably, it is probably the most powerful anti-obesity medication and type 2 diabetes medication on the market. It's like the next generation of Ozempic. They said... our stuff is commercially available, which set off a chain reaction of stopping the 503 manufacturing.

reported to the FDA that Manjaro and Zepbound, which Terzepatide, it's probably the, not probably, it is probably the most powerful anti-obesity medication and type 2 diabetes medication on the market. It's like the next generation of Ozempic. They said... our stuff is commercially available, which set off a chain reaction of stopping the 503 manufacturing.

And there's upwards, I have direct contact with all the people that are kind of at the upper echelons of these industries. The estimated amount of semaglutide compound scripts that were made in 2023 was 80 million. 80 million scripts for compounds of maglutide in 2023.

And there's upwards, I have direct contact with all the people that are kind of at the upper echelons of these industries. The estimated amount of semaglutide compound scripts that were made in 2023 was 80 million. 80 million scripts for compounds of maglutide in 2023.

And there's upwards, I have direct contact with all the people that are kind of at the upper echelons of these industries. The estimated amount of semaglutide compound scripts that were made in 2023 was 80 million. 80 million scripts for compounds of maglutide in 2023.

In one year. Now, that's not 80 million people. That's 80 million scripts. So divide that by 12. And then you sort of get how many, you know, prescriptions per year per people. But the other thing is... Terzepatide at that time is estimated to have been at about 30 million scripts. That's 2023. 2024, those numbers had to have jumped by conservatively 30%, probably more.

In one year. Now, that's not 80 million people. That's 80 million scripts. So divide that by 12. And then you sort of get how many, you know, prescriptions per year per people. But the other thing is... Terzepatide at that time is estimated to have been at about 30 million scripts. That's 2023. 2024, those numbers had to have jumped by conservatively 30%, probably more.

In one year. Now, that's not 80 million people. That's 80 million scripts. So divide that by 12. And then you sort of get how many, you know, prescriptions per year per people. But the other thing is... Terzepatide at that time is estimated to have been at about 30 million scripts. That's 2023. 2024, those numbers had to have jumped by conservatively 30%, probably more.

Yeah, right.